BioExx Announces Turnkey Engineering and Construction Contract for Oilseed and Protein Facility

    TORONTO, Oct. 4 /CNW/ - Bio-Extraction Inc. (BXI: TSX-V) ("BioExx") is
pleased to announce that it has contracted with Mentra Life Sciences Inc.
("Mentra") to complete all engineering, procurement and construction of its
previously announced 40,000 metric tonne Continuous Counter Flow ("CCF") oil
and protein extraction facility, to be constructed in Saskatchewan. The
project is expected to take approximately 12 months through to start-up of the
    Mentra ( is an engineering company that
provides custom project equipment and facilities to the advanced and emerging
Healthcare, Biopharma, Environment and Energy sectors on a turnkey basis.
Mentra has established strategic alliances with a number of carefully
pre-qualified companies who have a high reputation for their specialized high
quality products and technical expertise and Mentra has been recognized by
Canadian Government research and development agencies that have supported
their technical innovations. Further, they have earned a strong reputation
with advanced technology clients by creating custom pollution-free waste
treatment process systems and custom environmental solutions. This is an
important attribute as BioExx intends to establish and maintain best-in-class
emission standards in the oilseed industry with its unique extraction
    Although BioExx has not built a facility of this nature or size
previously, and the project will be subject to customary commercial and
economic risks with regard to timing, feasibility and profitability, Mentra
was responsible for the engineering design and control systems of the existing
Intermediate Size Plant (ISP), which BioExx utilizes for advanced R&D
purposes. Although the ISP operates on a continuous batch process, whereas the
new facility will be a CCF design, both facilities use substantially similar
thermodynamics and process flows, and Mentra is ideally suited to engineer and
manage construction of the CCF facility for BioExx. Mentra will work closely
with BioExx engineering and development personnel in all aspects relating to
design, procurement, construction, and start-up.
    "BioExx is very pleased to be working with Mentra on this project. Having
worked together on the difficult process of designing and operating the ISP,
which was a first of its kind facility to use the BioExx patented technology,
it is comforting to know that we will have such capable engineering partners
at our side as we construct our first CCF facility based on the same
principles," says BioExx President Chris Carl.

    About Bio-Extraction Inc.

    BioExx is involved in the development and commercialization of extraction
technology, which it intends to use to extract various active ingredients from
organic and inorganic materials, for its own account and as a service to
industrial customers. Global in scope, the BioExx target markets include
extractions in pharmaceutical, nutraceutical, food oils and fixed oils
(including bio-fuels) and industrial cleansing (eg. specialty steels). Versus
traditional technologies, the patented BioExx technology can offer lower
extraction costs, higher quality extracted materials, and material incremental
revenue opportunities as its extractions can substantially retain the value of
inherent proteins and other sensitive compounds - with all this being
completed in an environmentally responsible manner.
    To find out more about Bio-Extraction Inc. (TSX-V: BXI), please visit our
website at

    The TSX Venture Exchange has not reviewed this press release and neither
    approved nor disapproved the information contained in this press release.

    The statements made in this press release include forward-looking
statements that involve a number of risks and uncertainties. These statements
relate to future events or future performance and reflect management's current
expectations and assumptions. A number of factors could cause actual events,
performance or results to differ materially from the events, performance and
results discussed in the forward-looking statements, such as the economy,
generally, the demand for BioExx' products, the availability of funding, and
the anticipated costs of BioExx' plant construction and operation. These
forward-looking statements are made as of the date hereof and BioExx does not
assume any obligation to update or revise them to reflect new events or
circumstances. Actual events or results could differ materially from the
BioExx' expectations and projections.

For further information:

For further information: Chris Schnarr, Chief Financial Officer, BioExx,
(416) 588-4442, x.111,; Investor Relations: Scott Koyich,
President, Brisco Capital Partners, (403) 262-9888,;
or on the internet at AGORACOM Investor Relations,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890